These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 9088888)

  • 1. The serotonin syndrome and psychosis-like side-effects of fluvoxamine clinical use--an estimation of incidence.
    Ebert D; Albert R; May A; Merz A; Murata H; Stosiek I; Zahner B
    Eur Neuropsychopharmacol; 1997 Feb; 7(1):71-4. PubMed ID: 9088888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serotonin syndrome and fluvoxamine: a case study.
    Bastani JB; Troester MM; Bastani AJ
    Nebr Med J; 1996 Apr; 81(4):107-9. PubMed ID: 8628448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Fluvoxamine and serotonin syndrome in a patient with Parkinson disease].
    Le Cavorzin P; Sarkis S; Bénéton C; Pinel JF; Maruelle L; Le Vaou P; Allain H
    Therapie; 1996; 51(2):195-6. PubMed ID: 8763057
    [No Abstract]   [Full Text] [Related]  

  • 4. Polymorphisms in the 5-hydroxytryptamine 2A receptor and CytochromeP4502D6 genes synergistically predict fluvoxamine-induced side effects in japanese depressed patients.
    Suzuki Y; Sawamura K; Someya T
    Neuropsychopharmacology; 2006 Apr; 31(4):825-31. PubMed ID: 16205777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A single dose of fluvoxamine associated with an acute psychotic reaction.
    Sim FH; Massabki RA
    Can J Psychiatry; 2000 Oct; 45(8):762. PubMed ID: 11086561
    [No Abstract]   [Full Text] [Related]  

  • 6. Fluvoxamine: safety profile in extensive post-marketing surveillance.
    Buchberger R; Wagner W
    Pharmacopsychiatry; 2002 May; 35(3):101-8. PubMed ID: 12107854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case with occurring adverse effects when cross-over titration from fluvoxamine to paroxetine associated with increasing the plasma fluvoxamine level in major depressive disorder.
    Hori H; Yoshimura R; Ueda N; Ikenouchi-Sugita A; Umene-Nakano W; Nakamura J
    World J Biol Psychiatry; 2009; 10(4 Pt 2):620-2. PubMed ID: 18609433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Obsessive and compulsive symptoms in schizophrenia: a randomized controlled trial with fluvoxamine and neuroleptics.
    Reznik I; Sirota P
    J Clin Psychopharmacol; 2000 Aug; 20(4):410-6. PubMed ID: 10917401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypersalivation induced by olanzapine with fluvoxamine.
    Hori T; Makabe K; Nemoto K; Asada T
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jun; 30(4):758-60. PubMed ID: 16574294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful electroconvulsive therapy in major depression with fluvoxamine-induced bruxism.
    Miyaoka T; Yasukawa R; Mihara T; Shimizu Y; Tsubouchi K; Maeda T; Mizuno S; Uegaki J; Inagaki T; Horiguchi J; Tachibana H
    J ECT; 2003 Sep; 19(3):170-2. PubMed ID: 12972988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized double-blind fluvoxamine/placebo crossover trial in pathologic gambling.
    Hollander E; DeCaria CM; Finkell JN; Begaz T; Wong CM; Cartwright C
    Biol Psychiatry; 2000 May; 47(9):813-7. PubMed ID: 10812040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative study of the efficacy and safety profiles between fluvoxamine and nortriptyline in Japanese patients with major depression.
    Otsubo T; Akimoto Y; Yamada H; Koda R; Aoyama H; Tanaka K; Mimura M; Nakagome K; Kamijima K
    Pharmacopsychiatry; 2005 Jan; 38(1):30-5. PubMed ID: 15706464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Electrocardiographic findings during extended clinical trials of fluvoxamine in depression: one years experience.
    Hochberg HM; Kanter D; Houser VP
    Pharmacopsychiatry; 1995 Nov; 28(6):253-6. PubMed ID: 8773292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reboxetine versus fluvoxamine in the treatment of motor vehicle accident-related posttraumatic stress disorder: a double-blind, fixed-dosage, controlled trial.
    Spivak B; Strous RD; Shaked G; Shabash E; Kotler M; Weizman A
    J Clin Psychopharmacol; 2006 Apr; 26(2):152-6. PubMed ID: 16633143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An open study of fluvoxamine augmentation of neuroleptics in schizophrenia with obsessive and compulsive symptoms.
    Reznik I; Sirota P
    Clin Neuropharmacol; 2000; 23(3):157-60. PubMed ID: 10895399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concentration-response relationship for fluvoxamine using remission as an endpoint: a receiver operating characteristics curve analysis in major depression.
    Suzuki Y; Fukui N; Sawamura K; Sugai T; Watanabe J; Ono S; Inoue Y; Ozdemir V; Someya T
    J Clin Psychopharmacol; 2008 Jun; 28(3):325-8. PubMed ID: 18480690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Augmentative effects of fluvoxamine on duloxetine plasma levels in depressed patients.
    Paulzen M; Finkelmeyer A; Grözinger M
    Pharmacopsychiatry; 2011 Nov; 44(7):317-23. PubMed ID: 21979923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A double-blind study of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder.
    Milanfranchi A; Ravagli S; Lensi P; Marazziti D; Cassano GB
    Int Clin Psychopharmacol; 1997 May; 12(3):131-6. PubMed ID: 9248868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the efficacy, safety and physiological effects of fluvoxamine in social phobia.
    DeVane CL; Ware MR; Emmanuel NP; Brawman-Mintzer O; Morton WA; Villarreal G; Lydiard RB
    Int Clin Psychopharmacol; 1999 Nov; 14(6):345-51. PubMed ID: 10565801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Notes on the use of fluvoxamine as treatment of depression in HIV-1-infected subjects.
    Grassi B; Gambini O; Scarone S
    Pharmacopsychiatry; 1995 May; 28(3):93-4. PubMed ID: 7568371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.